The Pharma Data

NOVEMBER 30, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Vaccines Taskforce and National Institute for Health Research played pivotal roles in the rapid recruitment and enrollment of volunteers. and Australia.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

The Pharma Data

NOVEMBER 9, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. GAITHERSBURG, Md., Glenn, M.D., and globally.”. government.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Pharmaceutical Technology

AUGUST 17, 2022

These capabilities comprise cell and exosome genetic engineering for expressing therapeutic targets. In June 2020, AGC Biologics was selected by Novavax for large-scale production of an adjuvant for its Covid-19 vaccine candidate, NVX-CoV2373. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Manufacturing 130

Manufacturing Gene Therapy Genetic Engineering Gene 130

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Gene 262

Gene Gene Therapy Genetics DNA 262

Pharmaceutical Technology

MAY 2, 2023

IO agents include the classes of immune checkpoint modulators, cell therapies, bispecific antibodies, oncolytic viruses, therapeutic vaccines, and cytokines. All currently approved CAR-Ts are autologous, with the patient’s T-cells being genetically engineered to target antigens expressed by the cancerous cells.

Genetic Engineering 130

Genetic Engineering Antibody Clinical Trials Clinical Trials 130

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. IgG antibody responses are a useful marker of antigen exposure to diagnose immunodeficiency.

Gene Expression 130

Gene Expression Gene Genetic Engineering Antibody 130

The Pharma Data

DECEMBER 16, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, Novavax’ candidate vaccine against COVID-19. About NVX-CoV2373.

Protein 52

Protein Vaccination Vaccine Immune Response 52

pharmaphorum

MARCH 10, 2021

A laboratory study suggests Pfizer and BioNTech’s COVID-19 vaccine Comirnaty could be effective against a Brazilian variant of the SARS-CoV-2 virus – known as P.1 In February, the FDA issued guidelines allowing for faster development of updated coronavirus vaccines, while the EMA is also working on similar guidance for Europe.

Vaccination 66

Vaccination Vaccine Genetic Engineering Engineer 66

pharmaphorum

FEBRUARY 18, 2021

The South African coronavirus variant may cut the effectiveness of Pfizer/BioNTech’s vaccine by around two thirds, according to a laboratory study. In a response statement Pfizer and BioNTech noted that the COVID-19 vaccine did still provide protection in the lab study.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

Velocity Clinical Research

OCTOBER 3, 2024

With 220+ investigators, a global laboratory network, and sites with longstanding specialty research experience, Velocity can deliver patients for everything from large vaccine trials to focused cancer and rare disease trials involving genetically engineered therapies.

Gene Therapy 52

Gene Therapy Gene Genetic Engineering Clinical Research 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

Gene Splicing 130

Gene Splicing Gene DNA Recombinant DNA Technology 130

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% “Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. Glenn, M.D.,

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Genetics 130

Genetics DNA Genetic Engineering Antibody 130

Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. Gene Delivery Systems Genetic material, in the form of DNA or RNA, does not easily enter cells without the aid of a delivery system.

Engineer 52

Engineer Genetics Clinical Research Research 52

Roots Analysis

FEBRUARY 13, 2023

With the help of genetic engineering, synthetic mRNAs can express proteins, as they structurally resemble a natural mRNA. Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

Advarra

JUNE 13, 2023

Research in gene therapies and genetically engineered drugs and vaccines are growing exponentially, and will only continue to become more popular. When treatments involve recombinant or synthetic nucleic acids, including messenger RNA (mRNA) or viral vector vaccines, additional IBC oversight is necessary.

Gene Therapy 52

Gene Therapy Gene Research Genetic Engineering 52

The Pharma Data

SEPTEMBER 8, 2020

Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

— Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

Roots Analysis

FEBRUARY 26, 2024

Apart from being used in the traditional sense, for preventive purposes, novel vaccines have been developed for therapeutic use as well. A number of chronic degenerative conditions, such as cancer, are also being addressed using vaccines. The science of vaccinology has evolved significantly since Jenner’s discovery.

Medicine 52

Medicine Genetics Genetic Engineering Genetic Disease 52

The Pharma Data

JANUARY 10, 2021

Arcturus Therapeutics got the FDA go-ahead for its Phase II trial of its COVID-19 vaccine candidate ARCT-021. China’s Sinovac Biotech reported that its COVID-19 vaccine, CoronaVac, had a 78% efficacy rate in a Phase III clinical trial in Brazil. The new year began with a fairly low level of clinical trial news. Here’s a look.

Gene Therapy 52

Gene Therapy Trials Gene Clinical Trials 52

pharmaphorum

JANUARY 10, 2022

The deal comes amid the first glimmers that COVID-19 may be starting to become less of an emergency – at least in countries with high vaccination coverage that seem to be handling the Omicron wave without their healthcare systems being overwhelmed.

Trials 52

Trials Drugs Antibody Genetic Engineering 52

The Pharma Data

MARCH 29, 2022

In a preprint, the researchers at Cornell University led by Associate Professor Hector Aguilar-Carreno showed that genetically engineered mice infected with the virus causing COVID-19 and given a daily dose of the compound in a nasal spray for four days. 2 around the world.”

Genetic Engineering 52

Genetic Engineering Research Genetics Drugs 52

The Pharma Data

JANUARY 24, 2021

At Elasmogen we have been able to capture, using the latest protein and genetic engineering techniques, the immune system of 10,000 shark equivalents in a test-tube. It is therefore vital that we continue with drug discovery approaches in parallel with the global vaccination role out.”

Antibody 40

Antibody Protein Research Genetic Engineering 40

WCG Clinical

MAY 28, 2024

CAR-T Cells Target Harmful B Cells in Lupus CAR-T cell technology, which uses genetic engineering to direct white blood cells to attack specific molecular targets, was originally proposed for treatment of HIV infection and hematological malignancies.

In-Vivo 40

In-Vivo Clinical Trials Clinical Trials FDA Approval 40

The Pharma Data

OCTOBER 27, 2020

Clynes established the critical role of Fc receptor engagement underlying the efficacy of antitumor antibodies, providing the road map for the development of a new class of potency enhanced Fc engineered antibodies in cancer, including anti-CD20, anti-CD19 and anti-HER2 antibodies (obinutuzumab, tafacitamab, margetuximab). Dean A.

Antibody 40

Antibody Genetic Engineering Engineer Development 40

Advarra

AUGUST 10, 2023

Gene therapy has achieved notable successes, particularly in treating resistant or refractory B cell leukemias (achieving overall response rates around 90% or greater) and the speed with which COVID-19 vaccines were developed under the original Operation Warp Speed. Why Warp Speed for Rare Diseases?

Gene Therapy 52

Gene Therapy Development Gene Drugs 52

XTalks

AUGUST 17, 2020

protein-based biologics) and vaccine treatments. This typically involves taking T cells from the body, engineering chimeric receptor antigens (CAR) and inserting them into the cells, expanding the cells ex vivo and injecting them back into the body. Treatment vaccines : these boost the immune system responses to target cells.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Roots Analysis

SEPTEMBER 9, 2024

The rising demand for protein therapeutics, such as monoclonal antibodies and vaccines , is driving advancements in protein expression technology to ensure efficient and scalable production. Algal Expression System: This expression system is used in genetic engineering, biofuel production, botany.

Protein 40

Protein Gene Production DNA 40

Roots Analysis

OCTOBER 22, 2023

It is important to highlight that IVT mRNAs are structurally similar to natural mRNAs and can be used to express proteins through genetic engineering. RNA aptamers, on the other hand, are short RNA molecules that can bind to a specific protein, affecting its function.

RNA 40

RNA Protein Genetics Gene Expression 40

Scienmag

DECEMBER 22, 2020

Around a third of the world’s population carries Toxoplasma gondii, a parasite that puts people with a weakened immune system at risk and can trigger malformations in the womb. The single-celled pathogen also leads to economic losses in agriculture, with toxoplasmosis increasing the risk of abortion among sheep, for example.

Genetic Engineering 40

Genetic Engineering Engineer Genetics Allergies 40

Roots Analysis

JANUARY 27, 2025

Rising Demand for Biopharmaceuticals: The increasing demand for biologics including vaccines, insulin, and monoclonal antibodies, is one of the key factors driving the microbial fermentation industry. Microorganisms can be genetically engineered to produce complex biologics with high efficiency and lower costs.

Marketing 40

Marketing Manufacturing Production Development 40